Redeye expected a bit more in terms of top-line growth in Q2, which was softer than we have seen recently. Q2 sales grew by 14% proforma (vs. Q1’22 of 31%). Adjusted EBITDA was quite modest but still in positive territory. Business activity is high and Acuvi is preparing for a stronger second half of 2022. Our positive view on the case is intact, but our forecast adjustments have some negative impact on valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Acuvi - Preparing for a Stronger H2

© Modular Finance, source Nordic Press Releases